Hodgkin Lymphoma Program Objectives Brentuximab Vedotin in Hodgkin Lymphoma Brentuximab Vedotin in Patients With RR HL Brentuximab Vedotin Adverse Events Nivolumab in RelapsedRefractory HL Pembrolizumab in RelapsedRefractory HL ID: 499730
Download Presentation The PPT/PDF document "Improving Therapy Outcomes in Relapsed/R..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Improving Therapy Outcomes in Relapsed/Refractory Hodgkin LymphomaSlide2Slide3
Program ObjectivesSlide4
Brentuximab Vedotin in Hodgkin LymphomaSlide5
Brentuximab Vedotin in Patients With R/R HLSlide6Slide7
Brentuximab Vedotin: Adverse Events Slide8
Nivolumab in Relapsed/Refractory HLSlide9
Pembrolizumab in Relapsed/Refractory HLSlide10
Checkpoint Inhibitors: Adverse EventsSlide11
AETHERA Study: Brentuximab as Consolidation Therapy After ASCT Slide12
Ongoing Trials with Brentuximab Vedotin and Checkpoint Inhibitors in HLSlide13
Educating and Communicating With Patient With HLSlide14
Salvage Therapy With Brentuximab Followed By ChemotherapySlide15
Brentuximab + AVD vs ABVD in Advanced Stage HLSlide16
Survivorship in Patients With HLSlide17
Encouraging Shared Decision Making With PatientsSlide18
AbbreviationsSlide19
Abbreviations (cont)Slide20
ReferencesSlide21
References (cont)Slide22
References (cont)Slide23
References (cont)